Project Grant 2528179
Award Date 10/1/25
Completion Date 9/30/26
Dollars Obligated $305K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Ames, IA 50011, USA
Similar Awards
- This STTR Phase I project, awarded by the National Science Foundation (NSF) under the Technology, Innovation, and Partnerships (TIP) program (CFDA 47.084), aims to develop a novel vaccine platform to provide longer-lasting protection against infectious diseases. The $304,438 grant, awarded on October 1, 2025, supports Nitro Biosciences Inc.'s research to overcome limitations associated with immune imprinting, where prior exposure to pathogens can bias immune responses away from protective...
- This National Science Foundation (NSF) Small Business Technology Transfer (STTR) Phase I grant, awarded under the NSF Technology, Innovation, and Partnerships (CFDA 47.084) program, provides $274,991 to Duravax Inc. to develop thermostable formulations of mRNA vaccines and therapeutics. The project aims to overcome the cold-chain limitations of current mRNA products by demonstrating the feasibility of storing mRNA APIs and mRNA-lipid nanoparticles at room temperature for extended periods. If...
- The National Science Foundation awarded a $275,000 STTR Phase I grant to Inaedis, Inc. to develop an innovative method for the thermal stabilization of biopharmaceutical formulations. The project aims to establish a rapid room-temperature aerosol dehydration (RTAD) process that improves the stability of biologics, vaccines, and other pharmaceuticals, circumventing the need for a cold chain supply. This technology seeks to serve international markets by allowing the pharmaceutical industry to...
- This Small Business Innovation Research (SBIR) Phase I federal grant award from the National Science Foundation (NSF) under the NSF Technology, Innovation, and Partnerships (CFDA 47.084) program aims to develop a novel low-cost intradermal vaccine delivery platform for nucleic acid vaccines. The $304,742 award to Piezo Therapeutics, Inc. will demonstrate the feasibility of delivering naked nucleic acid vaccines without lipid nanoparticles using a handheld pen device. The project will optimize...
- This SBIR Phase II Cooperative Agreement award from the National Science Foundation (NSF) Technology, Innovation, and Partnerships (CFDA 47.084) program provides $996,606.00 to Invvax, Inc. to develop stable prophylactic antibodies (SPABs) that can serve as long-term preventatives for infectious diseases such as influenza, malaria, tuberculosis, HIV, and the common cold. The project aims to identify antibody mutations that can significantly enhance stability, extending the lifespan of antibodies...
- The National Science Foundation (NSF) awarded a $997,689 Cooperative Agreement under its NSF Technology, Innovation, and Partnerships (CFDA 47.084) program to Omnicyte LLC, a minority-owned small business in Branford, CT. The funding supports the design and production of a next-generation COVID-19 vaccine that addresses weaknesses of current vaccines, such as reduced booster effectiveness, short-lived efficacy, and side effects. The project aims to develop a vaccine candidate with improved...
- This National Science Foundation Project Grant of $255,927 awarded to Invvax, Inc. on March 1, 2022 seeks to develop stable prophylactic antibodies through February 2023. Funded through the NSF Engineering Directorate's CFDA 47.041 program, this Small Business Innovation Research Phase I project will engineer mutations to antibody Fc regions to resist degradation and enhance binding to the neonatal Fc receptor for potentially decades-long duration. Specifically, the awardee will combine known...
- This Project Grant from the National Science Foundation's Technology, Innovation, and Partnerships program totaling $256,000 will develop Recombinant BCG as a novel immunoadjuvant for viral infections. The awardee, Oncosting LLC located in Baltimore, Maryland, will optimize media and lyophilization manufacturing of BCG-STING, evaluate its immunological effects as an adjuvant for H1N1 influenza vaccination, and assess its protective effects as an H1N1 vaccine adjuvant. By adding stimulator of...
- This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $314,363 to Via Therapeutics, LLC, a for-profit limited liability company based in Austin, Texas, to develop a microneedle-based mRNA flu vaccine candidate for transcutaneous immunization. The goal is to create a stable, multivalent mRNA flu vaccine that can be administered intradermally using proprietary thin-film...
- This SBIR Phase I project, awarded by the National Science Foundation (NSF) under the NSF Technology, Innovation, and Partnerships (TIP) program (CFDA 47.084), aims to develop a method to turn on cancer immunotherapies only at the site of disease. The $275,000 award will support Synsorybio, Inc., a for-profit organization, in creating protein switches that activate immunotherapies in response to disease signals, rather than indiscriminately throughout the body. This approach seeks to improve the...